Comparative Pharmacology
Head-to-head clinical analysis: NITROGLYCERIN IN DEXTROSE 5 versus NITROMIST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NITROGLYCERIN IN DEXTROSE 5 versus NITROMIST.
NITROGLYCERIN IN DEXTROSE 5% vs NITROMIST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nitroglycerin is a vasodilator that relaxes vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase, increasing cGMP levels and causing venous and arterial dilation.
Nitroglycerin is a prodrug that releases nitric oxide (NO) which activates guanylyl cyclase, increasing cGMP in smooth muscle cells, leading to vasodilation primarily of venous capacitance vessels and coronary arteries.
Intravenous infusion: Initial 5 mcg/min, titrate by 5 mcg/min every 3-5 minutes to hemodynamic effect; usual maintenance 10-200 mcg/min. Sublingual: 0.3-0.6 mg every 5 minutes up to 3 doses. Topical: 1-2 inches every 8 hours.
1-2 sprays (0.4-0.8 mg) sublingually or intraorally at onset of angina, may repeat every 5 minutes up to 3 doses. Prophylaxis: 1 spray (0.4 mg) 5-10 minutes before activity.
None Documented
None Documented
Terminal elimination half-life: 1–4 minutes; clinical context: rapid clearance due to extensive metabolism by glutathione-S-transferase and glutathionylation.
2–3 minutes for nitroglycerin; rapid metabolism results in short terminal half-life. Clinically, effects dissipate within 30 minutes of discontinuation.
Renal: ~33% as intact drug; hepatic metabolism accounts for >90% of clearance; biliary/fecal: negligible.
Renal excretion of inactive metabolites accounts for >80% of elimination; biliary/fecal excretion is minimal (<15%).
Category C
Category C
Nitrate Vasodilator
Nitrate Vasodilator